SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new development or finding in product specification without further noticed.
Nome Químico: 5-O-Demethylavermectin A1a (> 80%) and 5-O-demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)avermectin A1a (< 20%); Spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran], avermectin B1 deriv
Sinônimo: Avermectin B1a-Avermectin B1b mixt.
Shipping Temperature: Ambient
HSN Code: 38229010
Country of Origin: India
Sorrisos: [H][C@@]1(O[C@H]2[C@H](C)O[C@@]([H])(O[C@H](/C(C)=C/C[C@@](C3)([H])O[C@@]4(C=C[C@H](C)C(O4)[C@@]([R])([H])C)C[C@H]3OC5=O)[C@@H](C)/C=C/C=C6CO[C@@]7([H])[C@]\6(O)[C@@]5([H])C=C(C)[C@H]7O)C[C@@H]2OC)O[C@@H](C)[C@H](O)[C@@H](OC)C1
Abamectin is chemically 5-O-Demethylavermectin A1a (> 80%) and 5-O-demethyl-25-de(1-methylpropyl)-25-(1-methylethyl)avermectin A1a (< 20%); Spiro[11,15-methano-2H,13H,17H-furo[4,3,2-pq][2,6]benzodioxacyclooctadecin-13,2'-[2H]pyran], avermectin B1 deriv. It is also known as Avermectin B1a-Avermectin B1b mixt.. Abamectin is supplied with detailed characterization data compliant with regulatory guideline. Abamectin can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Abamectin.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Stability of trifluro acetamide derivative products of abamectin and emamectin benzoate
By Fu, Qiang; Yang, Renbin; Zheng, Liguo; Yang, Yumei; Liu, Mengjia
From Nongyaoxue Xuebao (2013), 15(6), 708-712
Evaluation of degradation kinetics for abamectin in formulations using a stability indicating method
By Awasthi, Atul; Razzak, Majid; Al-Kassas, Raida; Harvey, Joanne; Garg, Sanjay
From Acta Pharmaceutica (Zagreb, Croatia) (2013), 63(1), 59-69